Effective May 15, 2023, Dr. Lisa Olson, Head of Research and Chief Scientific Officer of Magenta Therapeutics, Inc., has left the Company due to the completion of the sale of certain of Magenta's assets and its announced proposed merger with Dianthus Therapeutics, Inc.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.5 USD | +2.43% | -7.53% | +92.07% |
- Stock Market
- Equities
- MGTA Stock
- News Magenta Therapeutics
- Magenta Therapeutics, Inc. Announces Resignation of Lisa Olson as Head of Research and Chief Scientific Officer